一项针对过敏性和非感染性结膜炎患者的0.25%羟甲唑啉滴眼液双盲、多中心对照试验。
A double-blind, multi-centre controlled trial of 0.25% oxymetazoline ophthalmic solution in patients with allergic and non-infectious conjunctivitis.
作者信息
Breakey A S, Cinotti A A, Hirshman M, Skowron R A, Samson C R, Danzig M R
出版信息
Pharmatherapeutica. 1980;2(6):353-6.
Oxymetazoline (0.025%) ophthalmic solution, 2 drops 4-times daily, was compared with a placebo in the treatment of allergic and non-infectious conjunctivitis. In this 1 week, double-blind, multi-centre study, oxymetazoline proved significantly superior to the placebo (p < 0.001) in providing rapid and sustained clearing of inflamed conjunctiva. Overall, 84% of allergic patients treated with oxymetzoline were improved compared to 58% on placebo. Patients with non-infectious conjunctivitis exhibited a high degree of improvement (94%) compared to placebo (51%).
将0.025%的羟甲唑啉滴眼液，每日4次，每次2滴，与安慰剂对照，用于治疗过敏性和非感染性结膜炎。在这项为期1周的双盲、多中心研究中，羟甲唑啉在迅速且持续消除结膜炎症方面被证明显著优于安慰剂（p < 0.001）。总体而言，接受羟甲唑啉治疗的过敏性患者中84%病情改善，而接受安慰剂治疗的这一比例为58%。与安慰剂组（51%）相比，非感染性结膜炎患者使用羟甲唑啉后改善程度很高（94%）。
Zotero 插件